Earnings Feed
Start Free
VERTEX PHARMACEUTICALS INC / MA·4

Apr 17, 4:14 PM ET

Garber Alan M 4

Research Summary

AI-generated summary

Updated

Vertex (VRTX) Director Alan Garber Receives Award of 33.898 Units

What Happened

Alan M. Garber, a director of Vertex Pharmaceuticals (VRTX), was granted 33.898 deferred stock units (DSUs) on April 15, 2026. The grant is reported as a derivative award valued at $15,000 (33.898 units × $442.50 per unit). This was an award/grant (transaction code A), not an open‑market purchase or sale.

Key Details

  • Transaction date: 2026-04-15; Filing date (Form 4): 2026-04-17 (timely file).
  • Grant amount and price: 33.898 deferred stock units at $442.50 per unit; total reported value $15,000.
  • Shares owned after transaction: Not specified in the filing.
  • Footnote: Each deferred stock unit represents one share and will be paid in common stock upon the earliest of (i) Dr. Garber leaving the board, (ii) a change of control, or (iii) Dr. Garber's disability or death.
  • Transaction type: Derivative award (code A) — not an immediate cash transaction or sale.

Context

Deferred stock units are a form of compensation that convert to shares only upon certain triggering events; they do not represent currently tradable shares. This appears to be routine board compensation (modest dollar value) and should be viewed as a grant rather than a market bet. The filing was submitted within the typical Form 4 reporting window.